Abstract
Tumor necrosis factor-alpha (TNF-α) is critically involved in the pathogenesis of several chronic inflammatory diseases. Monoclonal antibodies against TNF-α are currently used for the treatment of rheumatoid arthritis and Crohn's disease. This report describes a simple and effective method for active immunization against self TNF-α. This vaccination approach leads to a T-cell–dependent polyclonal and sustainable anti–TNF-α autoantibody response that declines upon discontinuation of booster injections. The autoantibodies are elicited by injecting modified recombinant TNF-α molecules containing foreign immunodominant T-helper epitopes. In mice immunized with such molecules, the symptoms of experimental cachexia and type II collagen-induced arthritis are ameliorated. These results suggest that vaccination against TNF-α may be a useful approach for the treatment of rheumatoid arthritis and other chronic inflammatory diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Thorbecke, G.J. et al. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89, 7375–7379 (1992).
Williams, R.O., Feldmann, M. & Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784–9788 ( 1992).
Williams, R.O., Ghrayeb, J., Feldmann, M. & Maini, R.N. Successful therapy of collagen-induced arthritis with TNF receptor–IgG fusion protein and combination with anti-CD4. Immunology 84, 433–439 (1995).
Neurath, M.F. et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27, 1743 –1750 (1997).
Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36, 1681–1690 (1993).
Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147 ( 1997).
Targan, S.R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohńs disease. Crohńs Disease cA2 Study Group. N. Engl. J. Med. 337, 1029 –1035 (1997).
Elliott, M.J. et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1127 ( 1994).
Sette, A. et al. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 328, 395–399 (1987).
Shastri, N., Gammon, G., Horvath, S., Miller, A. & Sercarz, E.E. The choice between two distinct T cell determinants within a 23-amino acid region of lysozyme depends on their structural context. J. Immunol. 137, 911–915 (1986).
Ruff, M.R. & Gifford, G.E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J. Immunol. 125, 1671–1677 (1980).
Nemazee, D.A. & Burki, K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337, 562–566 ( 1989).
Goodnow, C.C. et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334, 676–682 (1988).
Dalum, I., Jensen, M.R., Hindersson, P., Elsner, H.I. & Mouritsen, S. Breaking of B cell tolerance toward a highly conserved self protein. J. Immunol. 157, 4796–4804 (1996).
Dalum, I. et al. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol 34, 1113– 1120 (1997).
Eck, M.J. & Sprang, S.R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J. Biol. Chem. 264, 17595–17605 (1989).
Bloom, J.W. Bettencourt, J.D. & Mitra, G. Epitope mapping and functional analysis of three murine IgG1 monoclonal antibodies to human tumor necrosis factor-α. J. Immunol. 151, 2707–2716 (1993).
Cerami, A., Ikeda, Y., Le Trang, N., Hotez, P.J., & Beutler, B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol. Lett. 11, 173– 177 (1985).
Staines, N.A. & Wooley, P.H. Collagen arthritis—what can it teach us? Br. J. Rheumatol. 33, 798– 807 (1994).
Lehmann, P.V., Forsthuber, T., Miller, A. & Sercarz, E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155–157 (1992).
Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184, 1397–1411 (1996).
Rothe, J. et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798–802 (1993).
Erickson, S.L. et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372, 560–563 (1994).
Panina-Bordignon, P. et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19, 2237–2242 (1989).
Williams, R.O., Williams, D.G. & Maini, R.N. Anti-type II collagen ELISA. Increased disease specificity following removal of anionic contaminants from salt-fractionated type II collagen. J. Immunol. Methods 147, 93– 100 (1992).
Acknowledgements
We wish to thank the technicians at M&E Biotech for excellent assistance and Dr. Anand Gautam and Dr. Gunilla Karlsson for useful comments on the manuscript. I.D. was supported by a grant from The Danish Natural Science Research Council, and M.F. and D.M.B. were supported by the Arthritis Research Campaign, UK.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dalum, I., Butler, D., Jensen, M. et al. Therapeutic antibodies elicited by immunization against TNF-α. Nat Biotechnol 17, 666–669 (1999). https://doi.org/10.1038/10878
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/10878
This article is cited by
-
Virus-like particle vaccinology, from bench to bedside
Cellular & Molecular Immunology (2022)
-
A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis
Scientific Reports (2015)
-
Beyond natural antibodies: the power of in vitro display technologies
Nature Biotechnology (2011)
-
Zinc-phosphate nanoparticles with reversibly attached TNF-α analogs: an interesting concept for potential use in active immunotherapy
Journal of Nanoparticle Research (2011)
-
A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis
Gene Therapy (2008)